Autoimmune Diseases  >>  Tresiba (insulin degludec)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tresiba (insulin degludec) / Novo Nordisk
BEGINâ„¢, NCT01079234 / 2009-012923-27: Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes

Checkmark
Feb 2013 - Feb 2013: 
Checkmark P3 data - EASD
Jul 2012 - Jul 2012: P3 data - EASD
Checkmark P3 data - EASD
More
Completed
3
493
US, Europe
insulin degludec, insulin glargine, insulin aspart
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
11/10
05/11
NCT01569841: A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes

Completed
3
24
US
insulin degludec, insulin glargine
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
11/12
11/12
SWITCH 1, NCT02034513 / 2012-001930-32: A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes

Hourglass Nov 2015 - Jun 2016 : SWITCH-1 trial
Completed
3
501
US, Europe
insulin degludec, insulin glargine, insulin aspart
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
01/16
01/16

Download Options